Optos announced the launch of Silverstone RGB for retinal imaging. In a press release, Optos said the device builds on the company's flagship Silverstone platform, and delivers a suite of 9 imaging modalities in a single device. According to the company, Silverstone RGB offers a broad spectrum of retinal imaging capabilities, enabling clinicians to capture, visualize, and analyze pathology across every layer of the retina.
The 9 modalities available with the Silverstone RGB device include: optomap color RGB for true-to-life retinal color imaging, optomap color RG, optomap fluorescein angiography for vascular evaluation and disease detection, optomap indocyanine green angiography for enhanced choroidal and vascular imaging, optomap sensory red-free for highlighting nerve fiber and vascular structures, optomap choroidal imaging for deep tissue visualization, optomap green autofluorescence for identifying RPE changes and metabolic activity, optomap blue autofluorescence for visualizing subtle retinal pathology, and swept-source OCT for high-resolution, navigable imaging anywhere in the retina.
“Silverstone RGB represents a transformative step forward for eyecare professionals,” said Masayuki Numako, director and executive vice president, Head of Healthcare Business Division, Nikon Europe B.V., in the press release. “By combining 200° single-shot ultrawidefield optomap technology, true-to-life color accuracy, and advanced swept-source OCT, clinicians can evaluate retinal pathology with unparalleled confidence, and efficiency.”
Optos said it will debut Silverstone RGB at the American Academy of Ophthalmology 2025 meeting in Orlando, Florida, and that the device will be available immediately in direct markets.